440 related articles for article (PubMed ID: 16373059)
1. Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.
Ots PM; Pérez AR; Carrizosa CL; Ocaña CV; de Dios Sáez Garrido J; Delgado Pérez JM
Clin Transl Oncol; 2005 Dec; 7(11):486-92. PubMed ID: 16373059
[TBL] [Abstract][Full Text] [Related]
2. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
Abdelrazik N; Fouda M
Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
[TBL] [Abstract][Full Text] [Related]
3. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
4. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Hudis CA; Vogel CL; Gralow JR; Williams D;
Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
8. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
9. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
Waltzman R; Croot C; Justice GR; Fesen MR; Charu V; Williams D
Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
[TBL] [Abstract][Full Text] [Related]
11. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
[TBL] [Abstract][Full Text] [Related]
12. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
13. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
14. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients.
Saag MS; Bowers P; Leitz GJ; Levine AM;
AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1037-45. PubMed ID: 15587490
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.
Provenzano R; Garcia-Mayol L; Suchinda P; Von Hartitzsch B; Woollen SB; Zabaneh R; Fink JC;
Clin Nephrol; 2004 Jun; 61(6):392-405. PubMed ID: 15224803
[TBL] [Abstract][Full Text] [Related]
18. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
19. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
Montoya VP; Xie J; Williams D; Woodman RC; Wilhelm FE
Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
Durmaz O; Demirkaya M; Sevinir B
Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]